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A nonhuman primate model for malaria vaccine development allowing reliable, stringent sporozoite chal-
lenge and evaluation of both cellular and antibody responses is needed. We therefore constructed a multicom-
ponent, multistage DNA vaccine for the simian malaria species Plasmodium knowlesi including two preeryth-
rocytic-stage antigens, the circumsporozoite protein (PkCSP) and sporozoite surface protein 2 (PkSSP2), and
two blood stage antigens, apical merozoite antigen 1 (PkAMA1) and merozoite surface protein 1 (PkMSP1p42), as
well as recombinant canarypox viruses encoding the four antigens (ALVAC-4). The DNA vaccine plasmids ex-
pressed the corresponding antigens in vitro and induced antiparasite antibodies in mice. Groups of four rhesus
monkeys received three doses of a mixture of the four DNA vaccine plasmids and a plasmid encoding rhesus
granulocyte-monocyte colony-stimulating factor, followed by boosting with a single dose of ALVAC-4. Three groups
received the priming DNA doses by different routes, either by intramuscular needle injection, by intramuscular
injection with a needleless injection device, the Biojector, or by a combination of intramuscular and intrader-
mal routes by Biojector. Animals immunized by any route developed antibody responses against sporozoites
and infected erythrocytes and against a recombinant PkCSP protein, as well as gamma interferon-secreting T-
cell responses against peptides from PkCSP. Following challenge with 100 P. knowlesi sporozoites, 1 of 12 experi-
mental monkeys was completely protected and the mean parasitemia in the remaining monkeys was significant-
ly lower than that in 4 control monkeys. This model will be important in preclinical vaccine development.
Malaria is a major cause of morbidity and mortality through-
out tropical and subtropical regions of the world, accounting
for an estimated 300 to 500 million infections and 1.5 to 3.0
million deaths annually (35). In the face of the spread of drug-
resistant malaria, efforts to develop an effective vaccine have
become increasingly critical. Two observations suggest that a
malaria vaccine may be achievable. First, immunization with
radiation-attenuated sporozoites induces sterile protection in
mice and humans (5, 17), mediated predominantly by CD81 T
cells and gamma interferon (IFN-g) and directed against the
intrahepatocytic stage of the parasite. Second, adults in areas
endemic for malaria develop partial clinical immunity, which is
largely mediated by antibodies directed against blood stage
antigens (23). A vaccine may need to induce both types of re-
sponses to provide optimal protection. DNA vaccines repre-
sent a flexible vaccine delivery system, capable of inducing both
antibodies and cell-mediated immune responses to a wide va-
riety of antigens. The flexibility of DNA vaccine technology
permits the combination of multiple antigens from both the
preerythrocytic and erythrocytic stages of the parasite. Previ-
ous studies from our laboratory have shown that DNA vaccines
directed against either preerythrocytic-stage antigens (7, 26) or
erythrocytic-stage antigens (1) can provide partial protection
in the Plasmodium yoelii murine-malaria model. A mixture of
DNA vaccines encoding four preerythrocytic-stage Plasmo-
dium falciparum antigens induced both antibodies and T-cell
responses to all four components in rhesus monkeys (32). In
human volunteers a DNA vaccine encoding the P. falciparum
circumsporozoite protein was safe and well tolerated and in-
duced antigen-specific cytotoxic-T-lymphocyte responses in the
majority of immunized volunteers (31). However, these first-
generation DNA vaccines are not optimally immunogenic or
protective; the PfCSP vaccine did not induce antibodies in
volunteers, and the protection induced by immunization with
P. yoelii DNA vaccines in mice is incomplete. Recent studies
have shown that the effectiveness of DNA vaccination against
malaria in mice can be increased by use of a prime-boost
strategy in which priming doses of DNA vaccine plasmids are
followed by a boost with recombinant poxvirus (25, 27). In
addition, inclusion of a plasmid encoding murine granulocyte-
monocyte colony-stimulating factor (GM-CSF) improves the
protection seen with the DNA vaccine alone (34). Finally,
combination of the two approaches further improves both pro-
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tection and immunogenicity (28). We therefore constructed a
set of DNA vaccines and recombinant canarypox virus to al-
low us to test the prime-boost approach in the Plasmodium
knowlesi/rhesus monkey model, a system in which both reliable
challenge with sporozoites and partial protection after immu-
nization with irradiated sporozoites have been demonstrated
(14). Because previous work involving Aotus monkeys with
malaria and hepatitis B DNA vaccines had suggested that the
route and method of administration can affect both the quality
and magnitude of the induced immune response (10, 11), we
studied three different methods of administering the priming
DNA, intramuscular (i.m.) injection with needle and syringe,
i.m. injection with the Biojector, a CO2-driven needleless in-
jection system (11, 12), and a combination of i.m. and intra-
dermal (i.d.) injection with the Biojector.
MATERIALS AND METHODS
Parasites and DNA. DNA from the H strain (4) of P. knowlesi was the kind gift
from Tom Templeton (National Institutes of Health, Bethesda, Md.). H strain
sporozoites and infected erythrocytes for immunofluorescence assay (IFA) were
provided by William Collins (Centers for Disease Control and Prevention, At-
lanta, Ga.). Infectious sporozoites for challenge were obtained by infection of
adult female Anopheles dirus mosquitoes (the kind gift from William Collins).
Construction of P. knowlesi DNA vaccine plasmids. The genes encoding the
circumsporozoite protein (PkCSP), sporozoite surface protein 2 (PkSSP2), and
apical merozoite antigen 1 (PkAMA1) and the gene fragment encoding the
42-kDa carboxy-terminal fragment of merozoite surface protein 1 (PkMSP1p42)
were amplified from P. knowlesi H strain genomic DNA by PCR using the
following primer pairs: PkAMAfp, CGGATCCATGAATAAAATATACTACA
TACT, and PkAMArp, GGGATCCTCAGTAGTAAGGCTTCTCCATCAG;
PkMSPfp, GGGATCCAAGAAGCAACTGGAGAATCACGTG, and PkMSPrp,
TGGATCCTTAGCTGGAAGAACTACAGAAAACTC; PkCSPfp, CGGATC
CATGAAGAACTTCATTCTCTTGGCCGTC, and PkCSPrp, GGGATCCTTA
ATTGAATAATGCTAGGACTAACAA; PvSSP2-10, CCTGGATCCATGAA
GCTACTTCAGAACAAAAGC, and PkSSP2rp2, TGGATCCTTATAACTTG
AACTGATCTGCCTCTCCAGCGTC. Primer pairs for PkCSP, PkAMA1, and
PkMSP1p42 were based on published sequences (2, 18, 33). The published par-
tial sequence of the H strain PkSSP2/TRAP lacks the 39 most N-terminal amino
acids (30). Therefore, for PkSSP2, the 59 PCR primer was based on the 59 se-
quence of the corresponding Plasmodium vivax gene, PvSSP2 (22). PCR products
were purified from preparative agarose gels and cloned into the pCR-Script
plasmid using the pCR-Script Amp SK(1) cloning kit (Stratagene) according to
the manufacturer’s instructions. The sequence of the cloned PCR product was
determined on an ABI Prism model 377 automated sequencer using the Dye
Terminator Cycle Sequencing kit (ABI, Warrington, United Kingdom). From
each pCR-Script clone, a BamHI fragment containing the desired P. knowlesi
antigen gene was excised and cloned into the BamHI site of DNA vaccine vector
VR1020 (16) to produce vaccine plasmids encoding PkCSP (VR2560), PkSSP2
(VR2561), PkMSP1p42 (VR2562), and PkAMA1 (VR2563). Vector VR1020
contains an expression cassette under the control of the promoter from the
cytomegalovirus intermediate/early 59 untranslated region including intron A
and flanked at the 39 end by the bovine growth hormone transcription terminator
element. In addition, VR1020 encodes the human tissue plasminogen activator
as a carboxy-terminal fusion with the inserted antigen gene. A plasmid encoding
rhesus GM-CSF (VR1722) was a kind gift from Richard Hedstrom (Naval
Medical Research Center, Silver Spring, Md.).
In vitro expression analysis. Expression of plasmid-encoded antigens was
qualitatively determined by immunoblot analysis of transiently transfected
UM449 human melanoma cell cultures as previously described (9, 16). Antigens
were detected by reaction with polyclonal murine antisera raised by immuniza-
tion of female CD-1 mice with plasmids encoding PkCSP, PkSSP2, PkAMA1,
and PkMSP1p42 as described below.
Construction of recombinant ALVAC-expressing P. knowlesi antigens. To op-
timize expression of foreign genes in recombinant canarypox virus ALVAC (19,
29), occurrences of the sequence TTTTTNT, which serves as an early transcrip-
tional terminator in vaccinia virus, must be modified. A single occurrence of this
sequence in PkAMA1 was mutagenized to alter the nucleotide sequence without
changing the encoded amino acid using the QuickChange mutagenesis kit (Strat-
agene, Inc., La Jolla, Calif.) and primers Pkmut1, GTCTCATTAATGACAAA
AATTTCTTTGCAACAACAGCGTTATCTC, and Pkmut2, GAGATAACG
CTGTTGTTGCAAAGAAATTTTTGTCATTAATGAGAC, according to the
manufacturer’s instructions. The remaining three P. knowlesi genes contain no
instances of the sequence TTTTTNT. A donor vector for recombination of genes
under the control of the modified H6 vaccinia virus promoter (13, 20), pC6L/H6,
was constructed. The complete H6 promoter was amplified from plasmid
pBSH6-1 (Virogenetics, Troy, N.Y.) with primers H6-1, CCGAATTCGATCC
CCCAACAAAAACTAATCAG, and H6-2, CGCTGCAGATATCGCGACCA
TGGGCCCATTACGATACAAACTTAACGG. The PCR product was cloned
into pCR-Script, the sequence was verified, and the EcoRI/PstI fragment con-
taining the H6 promoter was subcloned into the EcoRI/PstI site of pC6L (Viro-
genetics), an ALVAC donor plasmid containing a multiple cloning site flanked
by 1.1- and 0.4-kb sequences from the C6 region of the ALVAC genome. The
four P. knowlesi genes were amplified by PCR using primer pairs that included
bases 228 through 21 of the H6 promoter and cloned into NruI- or EcoRV-
digested pC6L/H6 to produce four donor plasmids, each containing a single
P. knowlesi gene under the control of the H6 promoter flanked by sequences
homologous to the C6 region of ALVAC. Each donor plasmid was used to
generate a recombinant ALVAC, ALVAC-PkCSP, ALVAC-PkSSP2, ALVAC-
PkAMA1, and ALVAC-PkMSP1p42 by in vitro recombination as described
previously (29). The mixture of the four P. knowlesi antigen-encoding ALVAC
viruses is designated ALVAC-4.
Animals and immunizations. Animals were used under protocols approved by
Institutional Use and Care of Animals Committees at facilities accredited by the
Association for the Assessment and Accreditation of Laboratory Animal Care
International. The experiments were conducted according to the principles set
forth by the Institute of Laboratory Animals Resources (12a). Female CD-1 mice
(6 to 8 weeks old; Charles River Laboratories, Wilmington, Mass.) were injected
i.d. with 50 mg of vaccine plasmid (1 mg/ml) in sterile saline in two sites at the
base of the tail at weeks 0, 4, and 8. Serum was taken for analysis prior to
immunization and 2 weeks after the second and third doses. Thirteen male and
3 female rhesus macaques (Macaca mulatta; Three Springs Scientific, Inc.,
Perkasie, Pa.; 18 to 33 months old, 3 to 4 kg) were divided into four groups of
four animals and immunized with either a mixture of the four P. knowlesi antigen
plasmids and the rhesus macacque GM-CSF plasmid, VR1722, at 500 mg/plasmid
(groups 1 to 3) or with 2 mg of VR1020 and 500 mg of VR1722 (group 4).
Immunization was either i.m. in the tibialis anterior muscle by needle and syringe
(group 1), i.m. by Biojector injection (group 2), or a combination of one i.m.
injection by Biojector containing 70% of the total dose and three separate i.d.
Biojector injections along the anterolateral aspect of the thigh, each containing
10% of the total dose (groups 3 and 4). DNA immunizations were given at weeks
0, 5, and 9. At week 35 the animals were boosted by i.m. injection (needle and
syringe) of either 2.5 3 108 PFU of each of four recombinant ALVAC expressing
the four P. knowlesi antigens (groups 1 to 3) or 109 PFU of parental ALVAC
(group 4).
Parasites and challenge. At week 40 sporozoites of P. knowlesi H strain were
dissected from the salivary glands of infected A. dirus mosquitoes in E199 me-
dium supplemented with 10% heat-inactivated, random-source, normal rhesus
macaque serum. For challenge, 100 sporozoites were injected into the saphenous
vein. Beginning on day 6 after challenge peripheral thick and thin blood films
were examined to determine parasitemia. Parasitemia in thick films was deter-
mined by the method of Earle and Perez (8) and in thin films was determined by
separate enumeration of infected and total erythrocytes. Animals were treated
with drugs when parasitemias reached 2% or higher.
IFA. Sera from immunized mice and monkeys were analyzed in IFAs against
air-dried sporozoites and infected erythrocytes as previously described (22).
PkCSP EIA. Ninety-six well enzymatic immunoassay (EIA) plates were coated
with recombinant PkCSP protein at 0.3 mg/ml in phosphate-buffered saline
(PBS), pH 7.0, for 6 h at room temperature, washed three times with 0.05%
Tween 20 (Sigma, St. Louis, Mo.) in PBS, and blocked overnight in 5% nonfat
dry milk in PBS at 4°C. Appropriate dilutions of test sera in 3% nonfat dried milk
in PBS were added to quadruplicate wells, and the plates were incubated at room
temperature for 2 h and washed three times with washing buffer. Plates were
incubated with horseradish peroxidase-conjugated goat anti-human immuno-
globulin G (Kirkegaard and Perry Laboratories, Gaithersburg, Md.) for 1 h at
room temperature, washed three times, and incubated for 20 min with ABTS
(2,29-azinobis[3-ethylbenzthiazolinesulfonic acid]) substrate solution (Kirke-
gaard and Perry Laboratories), and the optical densities at 405 nm (OD405) were
read. The background OD405 in wells treated with preimmune serum were
subtracted, and the means and standard errors of the means from the quadru-
plicate wells are reported.
IFN-g ELISPOT assay. IFN-g enzyme-linked immunospot (ELISPOT) assays
were carried out as previously described (15). The following peptide pools were
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used: pool 1, PkCSP amino acids (aa) 11 to 30, SILLVDLLPTHFEHNVDLSR,
aa 21 to 40, HFEHNVDLSRAINVNGVSFN, aa 41 to 60, NVDTSSLGAQ
QVRQSASRGR, and aa 51 to 70, QVRQSASRGRGLGEKPKEGA; pool 2,
PkCSP aa 71 to 90, DKEKKKEKGKEKEEEPKKPN, aa 91 to 110, ENKLKQP
NEGQPQAQGDGAN, aa 201 to 220, QGDGANAGQPQAQGDGANAG, aa
251 to 270, GGAPAGGNEGNKQAGKGQGQ, and aa 281 to 300, KVVNDYL
HKIRSSVTTEWTP; pool 3, PkCSP aa 306 to 325, GNGVRIRRKAHAGNK
KAEDL, aa 311 to 330, IRRKAHAGNKKAEDLTMDDL, aa 315 to 334, AHA
GNKKAEDLTMDDLEVEA, and aa 320 to 339, KKAEDLTMDDLEVEAC
VMDK. Means and standard deviations for quadruplicate wells are reported.
Statistical analyses. Differences between multiple groups were assessed by
one-way analysis of variance followed by Tukey’s honestly significant difference
test to identify which specific groups differed. Comparisons between two groups
were made using a two-tailed Student t test. Correlations between parasitemia
and measures of immune response were evaluated using the Pearson product
moment correlation. All statistical calculations were performed with SigmaStat,
version 2.03, for Windows (SPSS, Inc., Chicago, Ill.).
Nucleotide sequence accession numbers. The sequences of the PkMSP1 and
PkAMA1 H strain genes amplified in the vaccine plasmids were determined and
deposited in GenBank with accession no. AF298219 and AF298218, respectively.
The nucleotide sequence of the product of PCR amplification of the coding
sequence of PkSSP2 was deposited in GenBank with accession no. AF298217.
RESULTS
Construction of vaccine plasmids. Vaccine plasmids encod-
ing PkCSP, PkSSP2, PkMSP1p42, and PkAMA1 in the
VR1020 backbone were constructed as described in Materials
and Methods. For PkMSP1 and PkAMA1 PCR amplification
was performed with primers based on sequences from the Nuri
strain. The published sequence encoding H strain PkSSP2
lacked the sequence encoding 39 N-terminal amino acids (30).
The full-length sequence of PkSSP2 was amplified from H
strain DNA using a 59 PCR primer based on the P. vivax SSP2
sequence; the product was sequenced and was found to differ
from the published sequence at 3 nucleotides (2 synonymous
changes and 1 nonsynonymous change).
In vitro expression. We assessed the ability of the vaccine
plasmids to express the desired P. knowlesi gene products in
mammalian cells by in vitro transfection of melanoma cell line
UM449 and detection of products of the expected molecular
weights in denatured sodium dodecyl sulfate-polyacrylamide
gel electrophoresis Western blots with antisera raised against
DNA vaccine plasmids encoding the P. knowlesi antigens. Fig-
ure 1 shows that products of the expected sizes were detected
in UM449 cells transfected with plasmids encoding PkCSP (48
kDa), PkSSP2 (95 kDa), and PkMSP1p42 (42 kDa). As a check
against the circularity involved in using antisera derived from
immunization with a given plasmid to detect the in vitro ex-
pression products of the same plasmid, the antisera were tested
in IFAs against P. knowlesi sporozoites or infected erythrocytes
and were found to have the staining pattern expected for each
antigen (data not shown). As for a similar P. vivax AMA1 DNA
vaccine (22), no PkAMA1 product was detected in transient
transfection assays; however, as described below, immuniza-
tion with the PkAMA1 plasmid induced antibodies in mice,
which showed the expected apical fluorescence pattern in in-
fected erythrocytes. The ability of the four recombinant ALVAC
to express PkCSP, PkSSP2, PkAMA1, and PkMSP1p42 was
assessed by IFA and Western blotting of infected Vero cells
using murine antisera raised by immunization with DNA vac-
cine plasmids described above. All recombinant ALVAC ex-
pressed the corresponding P. knowlesi antigen; for ALVAC
PkAMA1, expression could be detected by IFA but not by West-
ern blotting (data not shown).
Murine immunogenicity. To confirm the in vivo expression
and immunogenicity of the P. knowlesi vaccine plasmids, we
immunized groups of five CD-1 mice with either a control
plasmid (VR1020), each of the individual plasmids encoding
PkCSP, PkSSP2, PkAMA1, and PkMSP1p42, or the combina-
tion of all four vaccine plasmids, designated tetravalent vac-
cine, Knowlesi (TVK). Mice were immunized intradermally at
the base of the tail with 50 mg of each plasmid three times at
4-week intervals. Sera were obtained 2 weeks after each im-
munization. Table 1 shows the results of IFA on sporozoites
and infected erythrocytes. Mice immunized with either the
PkCSP or the PkSSP2 plasmids alone or with TVK produced
moderate antisporozoite antibody titers (Table 1); the staining
patterns were as expected, diffuse surface staining for PkCSP
and patchy staining for PkSSP2. Surprisingly, antisera raised
against PkAMA1 also gave moderate antisporozoite antibody
titers with a distinctive apical staining pattern. Mice immu-
nized with either the PkMSP1p42 or PkAMA1 plasmids alone
or with TVK produced moderate anti-infected erythrocyte an-
tibody titers (Table 1) with the expected staining patterns, an
alveolar pattern for PkMSP1p42 and a spotty, apical pattern
for PkAMA1. Interestingly, antibodies raised against PkSSP2
did not react in blood stage IFA, consistent with the lack of
expression of PfSSP2 (24) and PySSP2 (3) in infected erythro-
cytes, in spite of the original description of PfSSP2 as a blood
stage antigen (21). Immunization with TVK induced compa-
rable or higher titers in response to both sporozoites and
infected erythrocytes than did immunization with the individ-
FIG. 1. In vitro expression of P. knowlesi candidate vaccine anti-
gens. UM449 cells were transfected either with a control plasmid (1020)
or with the indicated antigen plasmid (encoding PkCSP, PkSSP2,
PkAMA1, or PkMSP1p42). Protein extracts were prepared from cell
pellets (P) or culture supernatants (S) and subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis as described in Materials
and Methods. Antigen expression was detected with the antisera indi-
cated beneath each panel.
TABLE 1. Pooled IFA titers after three doses of P. knowlesi
vaccine plasmids in mice
Vaccine Sporozoite IFA titera Blood stage IFA titera






a Titer of pooled sera from five CD-1 mice.
b TVK, mixture of PkCSP, PkSSP2, PkAMA1, and PkMSP1p42.
c N.D., not done.
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ual stage-specific antigen plasmids (Table 1). Neither preim-
mune sera nor sera from mice immunized with the control
plasmid, VR1020, contained antibodies to sporozoites or in-
fected erythrocytes (Table 1).
Nonhuman primate immunogenicity. To assess the immu-
nogenicity and protective efficacy of this tetravalent vaccine in
nonhuman primates we conducted an immunization-and-chal-
lenge study with rhesus monkeys. Based on the results of
experiments with the P. yoelii murine model system, which
showed enhanced immunogenicity and protective efficacy
when a DNA vaccine encoding PyCSP was coinjected with a
plasmid encoding murine GM-CSF and boosted with a recom-
binant poxvirus expressing PyCSP (28), we used a similar im-
munization regimen with the TVK in rhesus monkeys. In the
trial described here, we varied only the route and method of
administration of the DNA; three groups of four monkeys
were immunized with the TVK and GM-CSF plasmids and
boosted with recombinant ALVAC as described in Materials
and Methods. One group received the DNA by i.m. injection
with needle and syringe, one group received it by i.m. injection
with the needleless Biojector device, and one group received it
by a combination of the i.m. and i.d. (i.m/i.d.) routes using the
Biojector. The group receiving the control vaccine received it
via the i.m./i.d. route.
Figure 2 shows the results of IFA and EIA analysis of sera
from the immunized monkeys. Preimmune sera and sera from
control immunized monkeys contained no detectable antibod-
ies to sporozoites (Fig. 2a) and minimal background titers
against infected erythrocytes (Fig. 2b). Following the third
dose of DNA the geometric mean antisporozoite and anti-
infected red blood (irbc) cell titers were highest in the group
immunized by the i.m./i.d. route (1:538 for sporozoites; 1:269
for irbc) although the difference between the two Biojector
groups, i.m. and i.m./i.d., was not statistically significant. Titers
in the i.m. needle group were barely detectable. Titers declined
toward baseline during the 6-month interval between the third
DNA dose and the poxvirus boost. Three weeks following the
ALVAC boost, geometric mean antisporozoite and anti-irbc
IFA titers were highest in the group which had received the
DNA prime i.m. by Biojector (1:7,241 for sporozoites, 1:2,560
for irbc; P 5 0.097 and 0.046, respectively, compared with
needle group by two-tailed t test); the difference between the
two Biojector groups was not statistically significant. The re-
sponse to PkCSP was analyzed by EIA using a recombinant
PkCSP as the target antigen. As shown in Fig. 2c, following the
third dose of DNA only the monkeys immunized with the
Biojector had significant antibodies to PkCSP. Following the
canarypox virus boost the highest ODs at a 1:100 dilution of
serum were observed in the i.m. Biojector group and were
statistically higher than those seen in the i.m./i.d. Biojector
group (P 5 0.049; two-tailed t test) and the i.m. needle group
(P 5 0.019; two-tailed t test).
Figure 3 and Table 2 show the results of IFN-g ELISPOT
assays on peripheral blood mononuclear cells (PBMC) from
the immunized monkeys. Neither preimmune PBMC nor
FIG. 2. Antibody responses in immunized rhesus monkeys. Shown
are IFA titers against P. knowlesi sporozoites (a) and P. knowlesi-in-
fected rhesus erythrocytes (b) and OD405 values obtained from a 1:100
dilution of serum in an EIA against recombinant PkCSP. Hatched
bars, geometric mean titers (a and b) or mean OD405 values (c) for
each group (i.m. needle, i.m. Biojector, i.m./i.d. Biojector, control);
circles, individual values from each animal. Serum samples were ob-
tained before immunization (PreImm), 2 weeks following the third
dose of DNA (Post 3rd DNA), immediately prior to the viral boost, 26
weeks after the last DNA dose (PreBoost), and 2 weeks following the
viral boost (Boost).
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PBMC obtained 2 weeks after administration of the third
DNA dose secreted IFN-g in response to the three peptide
pools (Fig. 3 and data not shown); following the recombinant
ALVAC boost, PBMC from 10 of 12 immunized monkeys
produced IFN-g-secreting cells at net frequencies ranging from
29 to 355 spot-forming cells (SFC)/106 PBMC. Table 2 sum-
marizes the results of ELISPOT assays carried out with the
three pools of peptides on PBMC obtained after the poxvirus
boosting of the animals. Three of 12 experimental monkeys
responded to peptide pool 1, 10 of 12 responded to pool 2, and
5 of 12 responded to pool 3 at net frequencies greater than the
mean plus 2 standard deviations of the net frequency in control
animals. There were no statistically significant differences in
the mean IFN-g responses between the three experimental
groups immunized by different routes.
Protective efficacy. Five weeks after the ALVAC boost the
monkeys were challenged by saphenous vein injection of 100 H
strain P. knowlesi sporozoites on day 0 of the challenge. Be-
ginning on day 6 daily peripheral blood smears, thick and thin,
were examined for P. knowlesi parasites. Animals were treated
when the parasitemia reached 2% or on day 14. The individual
parasitemias of the monkeys from days 7 to 12 are shown in
Table 3, and the mean parasitemias of each group are plotted
in Fig. 4. All of the control monkeys (4 of 4) and all but one
(PPG) of the TVK-immunized monkeys (11 of 12) became
parasitemic, and all but 2 of the parasitemic monkeys (1 con-
trol, KJT, and 1 from the i.m./i.d. Biojector group, TJX) re-
quired treatment for parasitemia greater than 2% on day 12 or
13 (range of parasitemia at time of treatment, 2 to 29%). On
each day of the parasitemic phase of the study, the mean
parasitemias in the experimental groups were lower than those
in the control group. Analysis of variance on the mean para-
sitemias on each of days 9 to 12, before any monkeys received
treatment, detected statistically significant differences between
groups (P 5 0.024, day 9; P 5 0.004, day 10; P 5 0.023, day 11;
P 5 0.048, day 12). The differences remained statistically sig-
nificant even if the monkey which did not develop parasitemia,
PPG, was excluded from the analysis. Application of Tukey’s
test identified statistically significant differences between the
control group and the i.m. Biojector group on days 9 to 12 (P 5
0.016, 0.004, 0.032, and 0.047, respectively) and between the
control group and the i.m. needle group on day 10 (P 5 0.010).
Comparison of control monkeys versus all 12 immunized mon-
keys by two-tailed t test also identified statistically significantly
lower parasitemias in the immunized monkeys on days 9 to 12
(P 5 0.010, 0.002, 0.003, and 0.007, respectively). In the group
with the lowest mean parasitemia, the i.m. Biojector group,
parasitemias were more than 10-fold lower than those in the
control group on days 9 to 12. In all groups, parasitemia in-
FIG. 3. IFN-g ELISPOT responses to pool 2 peptides. Shown are
the net numbers of IFN-g SFC per million PBMC (SFC in cells
incubated with peptides in pool 2 minus SFC in cells incubated with
medium alone). PBMC were obtained prior to immunization (Pre-
Imm), 2 weeks after the third DNA dose (Post DNA), and 2 weeks
after the viral boost (Boost). Hatched bars, mean values for each group
(i.m. needle, i.m. Biojector, i.m./i.d. Biojector, control); circles, indi-
vidual values from each animal. Standard deviations of quadruplicate
values for individual animals are shown in Table 2.
TABLE 2. IFN-g ELISPOT responses after boost of rhesus
monkeys with recombinant canarypox virus (ALVAC-4)
Route Monkey
Net IFN-g SFC/106 PBMC (SD)a
for pool:
1 2 3
Needle i.m. TCD 5 (1) 38 (5) 89 (7)
PEH 1 (3) 355 (15) 4 (2)
JGF 5 (4) 81 (6) 1 (3)
PTT 21 (2) 45 (9) 48 (8)
Biojector i.m. PWA 3 (1) 153 (2) 21 (1)
TJE 10 (2) 224 (5) 5 (1)
PPG 21 (3) 24 (2) 28 (2)
PWH 26 (4) 211 (7) 43 (3)
Biojector i.m./i.d. TJX 21 (1) 21 (1) 23 (1)
TXA 125 (13) 164 (18) 44 (12)
PVG 28 (7) 199 (12) 15 (6)
PJE 1 (1) 29 (2) 1 (1)
Control GKK 3 (1) 3 (1) 1 (1)
TXP 5 (0) 3 (0) 8 (1)
KCV 6 (2) 25 (2) 25 (2)
KJT 3 (1) 21 (1) 0 (1)
a Shown are the means and standard deviations (SD) of the net (peptide-
stimulated 2 medium control) values from quadruplicate wells. Values in bold-
face exceed the mean 1 2 SD of the control animals’ responses.
TABLE 3. Parasitemias following challenge with
P. knowlesi sporozoitesa
Monkey Route
Parasitemia (parasites/mm23) on day:
7 8 9 10 11 12
JGF Needle i.m. 0 8 24 464 5,600 136,000
PEH 0 24 24 112 2,680 43,000
TCD 0 8 64 656 30,800 325,200
PTT 0 0 0 208 528 7,300
PPG Biojector i.m. 0 0 0 0 0 0
PWH 0 0 0 248 1,440 32,400
TJE 0 0 8 224 1,600 22,100
PWA 0 8 8 136 3,120 47,000
PVG Biojector i.m./i.d. 0 56 56 1,968 4,800 245,200
PJE 0 64 48 488 17,680 121,000
TJX 0 8 16 1,080 27,200 68,200
TXA 0 0 0 72 880 14,500
GKK Control i.m./i.d. 0 24 96 2,184 95,600 1,000,000
KCV 0 32 88 1,528 52,800 538,400
KJT 0 40 64 2,776 21,360 68,600
TXP 0 32 24 1,136 25,100 329,200
a Shown are parasitemias determined from thick-film examination. Monkeys
were challenged on day 0 with 100 H strain P. knowlesi sporozoites.
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creased approximately 10-fold every 24 h, consistent with re-
lease of 10 merozoites from each infected erythrocyte in a 24-h
cycle in P. knowlesi.
Association between immune responses and parasitemia.
We attempted to identify immunological markers as correlates
of protection by correlating the mean parasitemia for each
monkey group on each of days 9 to 12 with each of six immu-
nological variables, geometric mean IFA titer for sporozoites
or infected erythrocytes, mean OD value at 1:100 dilution in
the PkCSP EIA, and mean frequency of IFN-g SFC in re-
sponse to each of three peptide pools. On each of days 9 to 12
there was a significant negative correlation between the IFN-g
response to peptide pool 2 and parasitemia (correlation coef-
ficients were 20.965 [P 5 0.035], 20.995 [P 5 0.0047], 20.989
[P 5 0.011], and 20.973 [P 5 0.027] on days 9 to 12, respec-
tively, by Pearson product moment correlation). No other im-
munological variable was significantly correlated with para-
sitemia.
DISCUSSION
We have demonstrated the immunogenicity and modest pro-
tective efficacy of a four-gene vaccination regimen consisting of
a DNA prime with canarypox virus boost in the P. knowlesi/
rhesus macaque malaria model system. This study was de-
signed to address the efficacy of this prime boost regimen and
to compare the levels of effectiveness of different methods of
administration of the DNA prime. We did not here separate
the effects of the several components of this regimen. In a
separate, recent study we addressed the effect of the addition
of the rhesus macaque GM-CSF plasmid to the prime and the
use of the recombinant canarypox virus in the boost phase of
the regimen. Preliminary results suggest that inclusion of the
rhesus macaque GM-CSF plasmid does not improve antibody
responses. Induction of optimal antibody responses requires
boosting with recombinant canarypox virus; significantly, how-
ever, even two doses of the recombinant canarypox virus given
without prior boosting with the DNA vaccine plasmids failed to
induce detectable antibodies to sporozoites or blood stage
parasites (unpublished results). Thus, the effect of the poxvirus
boost here was to amplify responses primed by DNA, rather
than to induce de novo immune responses.
Immunization of rhesus monkeys with the prime boost reg-
imen tested here induced antibodies against preerythrocytic-
and erythrocytic-stage P. knowlesi parasites and against a re-
combinant PkCSP protein and T cells which secreted IFN-g in
response to incubation with peptides from PkCSP. T cells
secreting IFN-g in response to pooled peptides from PkCSP
were detected in 11 of 12 monkeys following the recombinant
poxvirus boost at frequencies greater than the mean plus 2
standard deviations of the background frequencies found in
control monkeys. No detectable IFN-g responses were found
prior to the poxvirus boost; in this experiment, at least, DNA
vaccination alone failed to induce T-cell responses in rhesus
monkeys. The maximum frequencies of IFN-g SFC found in
this study were in the range of 200 to 350 SFC/106 PBMC.
These frequencies are approximately 10-fold lower than those
observed when a similar regimen involving DNA prime with
poxvirus boost was used to immunize mice against the P. yoelii
CSP in a murine malaria vaccine model (28). The study by
Sedegah et al. differs in several important respects from the
present study; in the murine study, a single antigen, PyCSP,
was used and the poxvirus used in the boost phase was an
attenuated vaccinia virus rather than the recombinant canary-
pox virus used here. It is not clear whether the lower responses
observed in the present study are the result of the different
levels of responsiveness to this approach in mice and monkeys,
to the use of recombinant canarypox virus rather than vaccinia
virus, or to possible antigenic competition between the four
antigens used in this study.
The vaccination regimen used here provided modest evi-
dence of protection. A single immunized monkey in the i.m.
Biojector group was completely protected against sporozoite
challenge. Among the remaining immunized monkeys there
was a lower mean parasitemia on each of days 9 to 12 of the
challenge phase. In the group which had the lowest para-
sitemias on each day, the i.m. Biojector group, parasitemias
were slightly more than 10-fold lower than those observed in
controls. Both the absence of parasitemia and the reduced
parasitemias in the vaccinated monkeys could, in principle, be
due to immune responses directed at either the preerythrocytic
or erythrocytic stages of the life cycle. However, the slopes of
the parasitemia curves (Fig. 4) do not appear to differ signifi-
cantly between the immunized and control groups, implying
that there was no effective growth-inhibitory response directed
against blood stage parasites. It therefore appears more likely
that the modest protection seen here was the result of a re-
sponse directed against the preerythrocytic stages, leading to a
reduced number of liver stage schizonts being released into the
circulation at the beginning of the blood stage infection. Given
an observed multiplication rate of approximately 10-fold in
24 h, 10-fold-lower parasitemias on any given day or a 1-day
delay in reaching equivalent parasitemias in the vaccinated
monkeys imply an approximately 90% reduction in the liver
stage parasite burden. It is interesting that the reduction in
parasitemia on each of days 9 to 12 correlated with the mag-
FIG. 4. Parasitemia in monkeys following challenge with 100
P. knowlesi sporozoites. Shown are means and standard deviations of
the parasitemias in each group of challenged monkeys, determined
from thick-film examination as described in Materials and Methods.
IM Biojector*, means and standard deviations of that group when the
single nonparasitemic monkey is excluded.
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nitude of the IFN-g response to the peptide pool to which the
majority of the immunized monkeys responded. This correla-
tion is not absolute at the level of the individual monkey,
however, as the sterilely protected monkey, PPG, made no
detectable IFN-g response to any of the peptide pools tested.
This correlation is consistent with experiments with the murine
P. yoelii system, which suggest that DNA vaccine-induced pro-
tection is IFN-g dependent (6, 28). There are limitations to the
analysis of T-cell immune responses presented here. First, we
examined only a subset of possible peptides from PkCSP; we
did not assess T-cell responses to PkSSP2 or to the two blood
stage antigens. It is possible that a better correlation between
T-cell responses and protection at the level of individual mon-
keys would have been evident if we had been able to evaluate
responses to all possible targets. Second, in the present exper-
iments we did not have sufficient numbers of prechallenge
PBMC to test the T-cell subset dependence of the IFN-g
response; in the several murine P. yoelii vaccine models,
preerythrocytic-stage protection is usually dependent on CD81
T cells but can be dependent on CD41 T cells (6). In experi-
ments carried out to develop the rhesus IFN-g ELISPOT as-
say, we found that the T-cell responses observed in monkeys
immunized by this DNA prime plus canarypox virus boost were
CD41 but not CD81 T cell dependent (15). As the IFN-g
ELISPOT assay used here is based on pools of 20-mer pep-
tides, it is possible that it is not optimal for detection of CD81
T-cell responses. Thus, although it appears that the partial
protection seen here was the result of an IFN-g-mediated
response directed against preerythrocytic-stage parasites in the
liver, the T-cell subset dependence and detailed mechanism of
protection remain to be elucidated.
A secondary goal of these experiments was to examine the
effect of delivering the priming DNA dose by three different
routes, i.m. injection by needle, i.m. injection by the needleless
Biojector device, and a combination of the i.m. (70% of dose)
and i.d. (30% of dose) routes by the Biojector. The route of
administration of the viral boost was i.m. by needle injection in
all groups. For all of the immune responses measured follow-
ing the viral boost the responses consistently followed the rank
order Biojector i.m. . Biojector i.m./i.d. . needle i.m. In
addition, on each of days 9 to 12 the lowest parasitemias were
seen in the Biojector i.m. group. The differences between the
i.m. Biojector and i.m./i.d. Biojector groups did not reach sta-
tistical significance for any immune system parameter mea-
sured. The difference between the i.m. Biojector and the i.m.
needle group was statistically significant for the IFA titer in
response to blood stage parasites (P 5 0.046; two-tailed t test
on log-transformed titers) and the PkCSP EIA (P 5 0.019;
two-tailed t test). In brief, there was a consistent trend for
delivery of the DNA priming dose by the i.m. Biojector route
to be more effective than the other routes by all tested mea-
sures of immune response, including protection. The trend,
however, reached statistical significance only in isolated com-
parisons between the i.m. Biojector and i.m. needle groups.
There are several possible reasons why neither the level of
immune response nor protection in this experiment was com-
parable to those seen in recent studies in the P. yoelii mouse
malaria model (27, 28). First, there may be differences in the
response of mice and monkeys to the DNA prime-plus-poxvi-
rus boost regimen. Second, the challenge with 100 P. knowlesi
H strain sporozoites may be more stringent than the challenge
with 100 P. yoelii nonlethal strain sporozoites used in the
mouse model. Finally, the recombinant canarypox virus used in
the boost phase here may be less immunogenic than the atten-
uated vaccinia virus used in the murine studies. We have there-
fore undertaken a study of a similar four-gene P. knowlesi
DNA prime-plus-virus boost vaccine regimen using recombi-
nant vaccinia virus rather than canarypox virus in the prime.
In brief, we have demonstrated the ability of a four-gene
DNA prime-plus-canarypox virus boost malaria vaccine regi-
men to induce both antibody and T-cell responses and partial
protection against sporozoite challenge. We thus have estab-
lished a nonhuman primate model for a multicomponent, mul-
tistage malaria vaccine in which it is possible to measure both
antibody and T-cell responses and in which, following sporo-
zoite challenge, it is possible to assess protective effects at both
the preerythrocytic and erythrocytic stages of the parasite life
cycle. In this experiment 1 of 4 controls did not require treat-
ment; pooling results from all challenges in this system, 17 of
18 controls required treatment (W. O. Rogers, unpublished
data). Given this occasional failure of controls to require treat-
ment, detection of very low levels of erythrocytic-stage protec-
tion may be difficult. P. knowlesi in rhesus macaques is not a
perfect model for P. falciparum in humans; at a genetic level it
is more closely related to P. vivax than to P. falciparum; it has
a quotidian rather than a tertian cycle in the blood; it is not a
reliable model for cerebral malaria; finally, it may be more
lethal in rhesus macaques than is P. falciparum in humans.
Nonetheless, we believe that this model will be an important
preclinical system with which to test enhanced vaccines and
vaccine delivery systems prior to selecting candidates for test-
ing in humans.
ACKNOWLEDGMENTS
This work was supported by Naval Medical Research Center Work
Unit STOF 6.2.622787A.0101.870.EFX and by a Cooperative Re-
search and Development Agreement between the Naval Medical Re-
search Center and Aventis Pasteur, Inc.
We thank Daniel Carucci for assistance with the automated count-
ing of the ELISPOTs, William Collins for providing A. dirus mosqui-
toes, John Sacci for assistance in dissection of mosquitoes and purifi-
cation of sporozoites, Richard Stout (Bioject, Inc., Portland, Oreg.) for
the gift of Biojector syringes, Brett Saladino, Angela King, Donald
Randolph, and Bryan Cosling for assistance in care of the rhesus
monkeys, Pradeep Rathore for help with production of recombinant
PkCSP, and Heidi Lee for technical assistance.
REFERENCES
1. Becker, S. I., R. Wang, R. C. Hedstrom, J. C. Aguiar, T. R. Jones, S. L.
Hoffman, and M. J. Gardner. 1998. Protection of mice against Plasmodium
yoelii sporozoite challenge with P. yoelii merozoite protein 1 DNA vaccines.
Infect. Immun. 66:3457–3461.
2. Blackman, M. J., E. D. Dennis, E. M. A. Hirst, C. H. Kocken, T. J. Scott-
Finnigan, and A. W. Thomas. 1996. Plasmodium knowlesi: secondary pro-
cessing of the malaria merozoite surface protein-1. Exp. Parasitol. 83:229–
239.
3. Charoenvit, Y., M. L. Leef, L. F. Yuan, M. Sedegah, and R. L. Beaudoin.
1987. Characterization of Plasmodium yoelii monoclonal antibodies directed
against stage-specific sporozoite antigens. Infect. Immun. 55:604–608.
4. Chin, W., P. G. Contacos, G. R. Coatney, and H. R. Kimball. 1965. A
naturally acquired quotidian-type malaria in man transferrable to monkeys.
Science 149:865.
5. Clyde, D. F., H. Most, V. C. McCarthy, and J. P. Vanderberg. 1973. Immu-
nization of man against sporozoite-induced falciparum malaria. Am. J. Med.
Sci. 266:169–177.
6. Doolan, D. L., and S. L. Hoffman. 2000. The complexity of protective im-
munity against liver-stage malaria. J. Immunol. 165:1453–1462.
VOL. 69, 2001 P. KNOWLESI MALARIA DNA-CANARYPOX VIRUS VACCINE 5571
 
 
7. Doolan, D. L., M. Sedegah, R. C. Hedstrom, P. Hobart, Y. Charoenvit, and
S. L. Hoffman. 1996. Circumventing genetic restriction of protection against
malaria with multi-gene DNA immunization: CD81 T cell, interferon-
gamma, and nitric oxide dependent immunity. J. Exp. Med. 183:1739–1746.
8. Earle, W. S., and M. Perez. 1932. Enumeration of parasites in the blood of
malarial patients. J. Lab. Clin. Med. 17:1124.
9. Felgner, P. L., T. R. Gadek, M. Holm, R. Roman, H. W. Chan, M. Wenz, J. P.
Northrop, G. M. Rongold, and M. Danielsen. 1987. Lipofectin: a highly
efficient, lipid-mediated DNA transfection procedure. Proc. Natl. Acad. Sci.
USA 84:7413–7417.
10. Gramzinski, R. A., D. C. Maris, D. Doolan, Y. Charoenvit, N. Obaldia, R.
Rossan, M. Sedegah, R. Wang, P. Hobart, M. Margalith, and S. Hoffman.
1997. Malaria DNA vaccines in Aotus monkeys. Vaccine 15:913–915.
11. Gramzinski, R. A., C. L. B. Millan, N. Obaldia, S. L. Hoffman, and H. L.
Davis. 1998. Immune response to a hepatitis B DNA vaccine in Aotus
monkeys: a comparison of vaccine formulation, route, and method of ad-
ministration. Mol. Med. 4:109–118.
12. Greenberg, R. S., L. G. Maxwell, M. Zahurak, and M. Yaster. 1995. Prean-
esthetic medication of children with midazolam using the Biojector jet in-
jector. Anesthesiology 83:264–269.
12a.Grossblatt, N. (ed.). 1996. Guide for the care and use of laboratory animals.
Institute for Laboratory Animal Resources, National Academy Press, Wash-
ington, D.C.
13. Guo, P. X., S. Goebel, S. Davis, M. E. Perkus, B. Languet, P. Desmettre, G.
Allen, and E. Paoletti. 1989. Expression in recombinant vaccinia virus of the
equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of
immunized animals. J. Virol. 63:4189–4198.
14. Gwadz, R. W., A. H. Cochrane, V. Nussenzweig, and R. S. Nussenzweig. 1979.
Preliminary studies on vaccination of rhesus monkeys with irradiated sporo-
zoites of Plasmodium knowlesi and characterization of surface antigens of
these parasites. Bull. W. H. O. 57(Suppl. 1):165–173.
15. Kumar, A., W. Weiss, J. A. Tine, S. L. Hoffman, and W. O. Rogers. 2001.
ELISPOT assay for detection of peptide specific interferon-secreting cells in
Rhesus macaques. J. Immunol. Methods 247:49–60.
16. Luke, C. J., K. Carner, X. Liang, and A. G. Barbour. 1997. An OspA-based
DNA vaccine protects mice against infection with Borrelia burgdorferi. J. In-
fect. Dis. 175:91–97.
17. Nussenzweig, R. S., J. Vanderberg, H. Most, and C. Orton. 1967. Protective
immunity produced by the injection of X-irradiated sporozoites of Plasmo-
dium berghei. Nature 216:160–162.
18. Ozaki, L. S., P. Svec, R. S. Nussenzweig, V. Nussenzweig, and G. N. Godson.
1983. Structure of the Plasmodium knowlesi gene coding for the circum-
sporozoite protein. Cell 34:815–822.
19. Paoletti, E., J. Taylor, B. Meignier, C. Meric, and J. Tartaglia. 1995. Highly
attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev. Biol.
Stand. 84:159–163.
20. Perkus, M. E., K. Limbach, and E. Paoletti. 1989. Cloning and expression of
foreign genes in vaccinia virus, using a host range selection system. J. Virol.
63:3829–3836.
21. Robson, K. J., J. R. Hall, M. W. Jennings, T. J. Harris, K. Marsh, C. I.
Newbold, V. E. Tate, and D. J. Weatherall. 1988. A highly conserved amino-
acid sequence in thrombospondin, properdin and in proteins from sporozo-
ites and blood stages of a human malaria parasite. Nature 335:79–82.
22. Rogers, W. O., K. Gowda, and S. L. Hoffman. 1999. Construction and im-
munogenicity of DNA vaccine plasmids encoding four Plasmodium vivax
candidate vaccine antigens. Vaccine 17:3136–3144.
23. Rogers, W. O., and S. L. Hoffman. 1999. Malaria vaccines, p. 439–493. In M.
Wahlgren and P. Perlmann (ed.), Malaria: molecular and clinical aspects.
Harwood Academic Publishers, London, United Kingdom.
24. Rogers, W. O., A. Malik, S. Mellouk, K. Nakamura, M. D. Rogers, A.
Szarfman, D. M. Gordon, A. K. Nussler, M. Aikawa, and S. L. Hoffman.
1992. Characterization of Plasmodium falciparum sporozoite surface protein
2. Proc. Natl. Acad. Sci. USA 89:9176–9180.
25. Schneider, J., S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M.
Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. Hill. 1998. Enhanced
immunogenicity for CD81 T cell induction and complete protective efficacy
of malaria DNA vaccination by boosting with modified vaccinia virus An-
kara. Nat. Med. 4:397–402.
26. Sedegah, M., R. Hedstrom, P. Hobart, and S. L. Hoffman. 1994. Protection
against malaria by immunization with plasmid DNA encoding circumsporo-
zoite protein. Proc. Natl. Acad. Sci. USA 91:9866–9870.
27. Sedegah, M., T. R. Jones, M. Kaur, R. Hedstrom, P. Hobart, J. A. Tine, and
S. L. Hoffman. 1998. Boosting with recombinant vaccinia increases immu-
nogenicity and protective efficacy of a malaria DNA vaccine. Proc. Natl.
Acad. Sci. USA 95:7648–7653.
28. Sedegah, M., W. Weiss, J. B. Sacci, Jr., Y. Charoenvit, R. Hedstrom, K.
Gowda, V. F. Majam, J. Tine, S. Kumar, P. Hobart, and S. L. Hoffman. 2000.
Improving protective immunity induced by DNA-based immunization: prim-
ing with antigen and GM-CSF-encoding plasmid DNA and boosting with
antigen-expressing recombinant poxvirus. J. Immunol. 164:5905–5912.
29. Taylor, J., B. Meignier, J. Tartaglia, B. Languet, J. VanderHoeven, G.
Franchini, C. Trimarchi, and E. Paoletti. 1995. Biological and immunogenic
properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-
avian species. Vaccine 13:539–549.
30. Templeton, T. J., and D. C. Kaslow. 1997. Cloning and cross-species com-
parison of the thrombospondin-related anonymous protein (TRAP) gene
from Plasmodium knowlesi, Plasmodium vivax, and Plasmodium gallinaceum.
Mol. Biochem. Parasitol. 84:13–25.
31. Wang, B., D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y.
Charoenvit, T. R. Jones, P. Hobart, M. Margalith, J. Ng, W. R. Weiss, M.
Sedegah, C. de Taisne, J. A. Norman, and S. L. Hoffman. 1998. Induction of
antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vac-
cine. Science 282:476–480.
32. Wang, R., D. L. Doolan, Y. Charoenvit, R. C. Hedstrom, M. J. Gardner, P.
Hobart, J. Tine, M. Sedegah, V. Fallarme, J. B. Sacci, Jr., M. Kaur, D. M.
Klinman, S. L. Hoffman, and W. R. Weiss. 1998. Simultaneous induction of
multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by
immunization with a mixture of four Plasmodium falciparum DNA plasmids.
Infect. Immun. 66:4193–4202.
33. Waters, A. P., A. W. Thomas, G. H. Mitchell, and T. F. McCutchan. 1991.
Intra-generic conservation and limited inter-strain variation in a protective
minor surface antigen of Plasmodium knowlesi merozoites. Mol. Biochem.
Parasitol. 44:141–144.
34. Weiss, W. R., K. J. Ishii, R. C. Hedstrom, M. Sedegah, M. Ichino, K.
Barnhart, D. M. Klinman, and S. L. Hoffman. 1998. A plasmid encoding
murine granulocyte-macrophage colony-stimulating factor increases protec-
tion conferred by a malaria DNA vaccine. J. Immunol. 161:2325–2332.
35. World Health Organization. 1994. World malaria situation in 1992. Wkly.
Epidemiol. Rec. 69:309–314.
Editor: W. A. Petri, Jr.
5572 ROGERS ET AL. INFECT. IMMUN.
 
